An interventional study of Inspire System in Obstructive Sleep Apnea, OSA and Sleep Apnea, sponsored by Inspire Medical Systems, Inc.. Completed at 2 sites in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Inspire Medical Systems, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc. — 5 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · Inspire Medical Systems, Inc..
Among the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc., this one is the only one that started in 2024, is one of 6 with no phase, and was the 10th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →5 of the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc. are open now, in 8 countries. Recruiting first, the newest first:
Inspire Medical Systems, Inc. · Sites in United States
Ages 18+
Inspire Medical Systems, Inc. · Sites in Austria, Belgium, France and 4 more countries
Ages 18+
Inspire Medical Systems, Inc. · Sites in United States
Ages 13–18
Inspire Medical Systems, Inc. · Sites in United States
Ages 18+
Inspire Medical Systems, Inc. · Sites in United States
Ages 18–21
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2024.
This study's enrollment of 44 is below the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 60 across the 9 interventional studies, 535 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Inspire Medical Systems, Inc. is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, multicenter, open-label study designed to confirm device performance of Inspire system in Singapore.
Patients who meet study eligibility criteria will be implanted with an Inspire system and followed for 6 months post-therapy-activation. Study subjects will undergo in-lab sleep studies to confirm inspiratory overlap (1st PSG, after therapy activation), titrate the therapy (2nd PSG, at 3 months post-activation) and confirm therapy performance (3rd PSG, at 6 months post-activation). Symptoms and quality of life (assessed by ESS and FOSQ), therapy adherence, and adverse events will also be collected and reported.
Main Inclusion Criteria:
Main Exclusion Criteria:
Other eligibility criteria may apply.
Device: Inspire System
Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.
Inspiratory Overlap
Percentage (%) of inspiratory overlap as measured by polysomnography (PSG)
Time frame: 0-3 months post-therapy activation
Therapy Effectiveness
Change in Apnea-Hypopnea Index (AHI)
Time frame: 6 months post-therapy activation
Symptom Reduction
Mean Epworth Sleepiness Scale (ESS) Score of less than 10. ESS scores range from 0-24 with a score of less than 10 indicating normalized daytime sleepiness.
Time frame: 6 months post-therapy activation
Rate of Adverse Events
Report of procedure/device/therapy-related adverse events
Time frame: 6 months post-therapy activation
Therapy Adherence
Mean therapy use (hours per day)
Time frame: 6 months post-therapy activation
Functional Outcomes of Sleep Questionnaire (FOSQ) Score
Changes in Functional Outcomes of Sleep Questionnaire (FOSQ). Total score range 5-20, with higher scores indicating better functional status.
Time frame: 6 months post-therapy activation
Inspiratory Overlap
Percentage (%) of inspiratory overlap as measured by polysomnography (PSG)
Time frame: 6 months post-therapy activation
Plan to share: No — IPD will not be shared.
No publications or documents are linked to this record.
Ran from Jul 2024 to primary completion in Jul 2025, 11 months.
Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 11 months is close to that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inspire Medical Systems, Inc.